Navigating the Evolving Landscape of Clinical Trials in the Age of Technology

By Brendan Tarte, U.S. life sciences underwriter, Beazley

As the world emerges from the pandemic, clinical trials have resumed with renewed vigor. However, the integration of technology has fundamentally reshaped how these trials are conducted. The use of electronic health records (EHRs), algorithms, and machine learning has opened new avenues for data collection and patient engagement. While these advancements promise to enhance trial efficiency and participant safety, they also introduce a spectrum of new risks.

The Shift Towards Virtual and Decentralized Trials

One significant trend is the increasing move toward virtual and decentralized trials. This shift enables participants to contribute from their homes, cutting down on the need for travel. While this can enhance accessibility, it comes with risks. Concerns about the safety of at-home dosing and the security of the data collected are paramount. Vulnerabilities in remote data management can compromise trial integrity and patient safety.

The Role of Wearable Devices in Patient Monitoring

Wearable technology—think smartwatches and fitness trackers—has taken center stage in gathering real-time health data. These devices facilitate continuous monitoring, providing researchers with a wealth of information about participants’ activities. However, the reliance on technology raises critical questions about data security and the potential for technology failure. Risk managers must consider how to act on adverse events that may arise when patients aren’t physically monitored in a clinical setting.

Embracing Digital Health Technologies (DHTs)

The integration of digital health technologies, including mobile apps and telemedicine, is transforming the clinical trial landscape. These tools enable remote data collection and foster communication between participants and researchers. Yet, they bring forth issues of accountability. For instance, if a security breach occurs with third-party software, determining responsibility can become complicated. Effective vendor management and security protocols are crucial to mitigate these risks.

Harnessing Big Data and Artificial Intelligence

Artificial intelligence and Big Data are revolutionizing how trials are designed and conducted. Algorithms can analyze massive data sets to extract meaningful patterns, predict outcomes, and optimize participant selection. This could lead to breakthroughs in personalized medicine. However, the ethical considerations surrounding data use, including potential biases in algorithms, remain significant concerns for researchers.

Exploring Personalized Medicine

The focus on personalized medicine is reshaping treatment protocols, aiming to tailor therapies to individual patients. By considering genetic information and lifestyle factors, researchers endeavor to improve treatment efficacy while minimizing adverse effects. Nonetheless, ethical dilemmas, especially regarding information privacy and the usage of virtual monitoring tools, require careful navigation.

The Rise of Patient-Centric Approaches

Today’s clinical trials prioritize patient input, making them more patient-centric. The growing reliance on real-world evidence (RWE) ensures that trials resonate with patient experiences and clinical insights. While this enhances the understanding of treatment effectiveness, it introduces challenges related to data accuracy. Misidentifying participants based on flawed data can lead to skewed results and ineffective trials.

Addressing Emerging Risks

In navigating these trends, it is essential to implement safeguards that prioritize privacy, transparency, and accountability. Alongside technological advancements, robust risk management practices remain vital. This includes evaluating how new technologies are integrated into trials and ensuring adequate insurance coverage.

Key Considerations for Risk Managers

Here are salient questions risk managers should consider for comprehensive protection:

1. Technology Usage: How is technology incorporated into the trial? Is it proprietary or a third-party service?

2. Liability Management: How are liabilities handled through contracts and agreements?

3. Patient Contact: What levels of contact involve patient interaction? Are there malpractice exposures?

4. Telehealth Services: Will remote monitoring be part of this trial?

5. Insurance Coverage: Is the main insurance policy adequate, or do other parties need additional coverage?

Types of Insurance Coverage to Consider

Insurance needs will vary based on the answers to these questions. Typically, risk managers should seek policies that encompass:

• Product Liability Insurance: Covers bodily injury and property damage arising from the study drug or medical device usage.

• Errors and Omissions Insurance: Protects against litigation arising from services performed or advice given during the trial.

• Healthcare Professional Liability: Offers coverage against bodily injury claims from services rendered during the trial.

• Tech Errors & Omissions Insurance: Addresses financial injuries stemming from technology-related failures.

• Cyber Liability Insurance: Safeguards against data breaches impacting patient information.

Brokers play an invaluable role in guiding clients through this complex landscape, offering insights into insurance products that can mitigate emerging risks.

Embracing Change

Research institutions, universities, and clinical research organizations (CROs) are increasingly exploring innovative solutions to enhance clinical trial efficiency and patient engagement. By partnering with brokers to understand and address risks, life sciences companies can navigate the complex terrain introduced by technological advancements, ensuring they remain at the forefront of clinical research.